Status:
RECRUITING
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
Lead Sponsor:
Aardvark Therapeutics, Inc.
Conditions:
Hyperphagia
Prader-Willi Syndrome
Eligibility:
All Genders
13+ years
Phase:
PHASE3
Brief Summary
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us ...
Eligibility Criteria
Inclusion
- Patients who have completed treatment on Aardvark Therapeutics clinical study AVK-101-301
Exclusion
- Any complications that makes participation unsafe in the Investigator's opinion
Key Trial Info
Start Date :
July 23 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT07197034
Start Date
July 23 2024
End Date
April 1 2027
Last Update
January 8 2026
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's of Alabama
Birmingham, Alabama, United States, 35233-1711
2
Stanford Children's Health Specialty Services
Palo Alto, California, United States, 94304
3
Rady Children's Hospital
San Diego, California, United States, 92123
4
Children's Hospital Colorado
Denver, Colorado, United States, 80045-7106